Morgan Stanley Vascular Biogenics Ltd. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.21 - $0.32 $24,339 - $37,088	-115,900 Reduced 35.44%	211,111 $50,000
Q2 2023 Aug 14, 2023	SELL	$0.15 - $0.27 $12,300 - $22,140	-82,000 Reduced 20.05%	327,011 $75,000
Q1 2023 May 15, 2023	SELL	$0.13 - $0.19 $2,678 - $3,914	-20,600 Reduced 4.8%	409,011 $69,000
Q4 2022 Feb 14, 2023	BUY	$0.11 - $0.16 $5,687 - $8,272	51,700 Added 13.68%	429,611 $51,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $2.1 $33,315 - $466,410	-222,100 Reduced 37.02%	377,911 $59,000
Q2 2022 Oct 27, 2022	SELL	$1.22 - $1.95 $19,032 - $30,420	-15,600 Reduced 2.53%	600,011 $966,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.95 $19,032 - $30,420	-15,600 Reduced 2.53%	600,011 $966,000
Q1 2022 Oct 27, 2022	BUY	$1.15 - $1.97 $17,940 - $30,732	15,600 Added 2.6%	615,611 $1.04 Million
Q1 2022 May 13, 2022	SELL	$1.15 - $1.97 $31,973 - $54,771	-27,803 Reduced 4.32%	615,611 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$1.92 - $2.53 $62,970 - $82,976	-32,797 Reduced 4.85%	643,414 $1.27 Million
Q3 2021 Nov 15, 2021	BUY	$1.94 - $2.55 $1.31 Million - $1.72 Million	676,211 New	676,211 $1.39 Million

416K

Ticker VBLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,348,896
Description
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antib...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.